Check out the latest news and information from the Foundation by liking us on Facebook!
(2016) The Cutaneous Lymphoma Foundation's CEO Susan Thornton shared her experience living with cutaneous lymphoma in the online publication VOX. The article, "The way we think about cancer is outdated. Here's how to change that," explores how individuals learn to live with their cancer.
(2016) The ASH Annual Meeting is the world's premier event in malignant and non-malignant hematology. The meeting provides an invaluable educational experience for medical professionals and researchers from around the globe and an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.
This year's ASH meeting included several exciting advancements in research related to cutaneous lymphoma treatment. Below are highlights, click on the links to learn more.
Seattle Genetics reported exciting results in their clinical trials of Brentuximab Vedotin (Adcetris). According to the findings from the phase 3 ALCANZA trial, Brentuximab vedotin induced repsonses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician's choice of standard therapies. "These compelling results have potential practice-chaning implications for the use of brentuximab vedotin in managing CD30-expressing CTCL in patients who require systemic therapy," lead study author Youn H. Kim, MD, Stanford University School of Medicine, said when presenting the results at ASH.
Click here to read the press release.
Click here to read presented report.
Innate Pharma SA announced that clinical data for IPH4102 was presented in a poster by Dr. Youn Kim at ASH. IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 95% of certain aggressive CTCL subtypes, in particular, Sézary Syndrome and transformed mycosis fungoides. IPH4102 is in Phase 1 clinical trials and the current assessment shows postive outcomes. Click here to learn more.
Merck presented updated findings on KEYTRUDA® (pembrolizumab) for patients with relapsed or refractory Primary mediastinal large B-cell lymphoma. While the current focus of research does not include cutaneous lymphoma, it will be included in the future. Click here to learn more about the current study.
The two largest scientific medical meetings held each year are the annual T-Cell Symposium in January and the Cutaneous Lymphoma Workshop hosted by the United States Cutaneous Lymphoma Consortium in March.
The T-Cell Symposium brought together clinicians and researchers from 18 different countries and included discussions about all types of T-cell lymphomas, including cutaneous lymphomas.
In general, it was noted that T-cell lymphomas are rare diseases requiring international collaboration in order to improve the fundamental understanding of the biological mechanism or mechanisms that lead to their occurrence.
Both meetings provided updates and discussion about new findings in these biological disease mechanisms, new treatments under development and in clinical trials as well as international efforts to collaborate on projects that incorporate data from a wide range of clinical centers.
Susan Thornton, CLF's CEO, attended both meetings on behalf of the Foundation. Click here to read her highlights from the meetings.
Seattle Genetics, Inc. (Nasdaq:SGEN) announced that the company and its collaborator, Takeda Pharmaceutical Company Limited (Takeda), completed patient enrollment in the phase 3 ALCANZA clinical trial. ALCANZA is a randomized trial evaluating ADCETRIS (brentuximab vedotin) versus investigator’s choice of methotrexate or bexarotene in 132 patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) who received prior systemic therapy. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on skin lesions in at least 50 percent of patients with CTCL. The ALCANZA trial is being conducted under a Special Protocol Assessment (SPA) agreement from the U.S. Food and Drug Administration (FDA).
Click here to read more about study.
Adaptive Biotechnologies and collaborators at Brigham and Women’s Hospital announced publication of a study demonstrating that the company’s revolutionary immunosequencing platform, which utilizes next-generation sequencing and advanced bioinformatics to sensitively profile all of the T cells in a biological sample, adds value in delivering more definitive diagnoses of cutaneous T-cell lymphoma (CTCL).
The new study, published in Science Translational Medicine, showed that Adaptive’s technology detected a high-frequency T-cell clone in 100 percent of confirmed CTCL patients and could successfully discriminate CTCL from benign inflammatory skin diseases, such as psoriasis and contact dermatitis. The sequencing-based method was also able to distinguish early CTCL recurrence from benign inflammation, as well as detect CTCL cells in the blood of patients in which the disease had spread.
Click here to read more about Adaptive's study.
The European Organization for Research and Treatment of Cancer (EORTC) and Cutaneous Lymphoma Task Force (CLTF) scientific meeting convened in Turin, Italy for four days in September. Researchers, scientists, and clinicians from all over the world gathered to share research findings and clinical data. This year’s meeting included 84 oral presentations and 29 posters representing research work from 15 countries.
In addition to the scientific presentations, the meeting focused on fostering discussion and exchange of ideas among the participants, who don’t often have the opportunity to connect and discuss the potential for new international cooperative projects that fuel the future of therapeutic and diagnostic treatments. It was encouraging to see young clinicians and researchers presenting their research and showing a devoted interest in studying cutaneous lymphoma.
Susan Thornton, CLF's CEO, attended the EORTC Annual Meeting on behalf of the Foundation. Click here to read her highlights from the meeting.
A Phase I trial shows promising results for resiquimod gel in resolving lesions from cutaneous T-cell lymphoma (CTCL). The treatment caused disease regression, eradicated malignant T cells, and enhanced T cell effector function in 12 patients with stages IA to IIA disease. The clinical trial was conducted by researchers at the Perelman School of Medicine at the University of Pennslyvania and was co-led by Rachael Clark, MD, PhD, Associate Professor of Dermatology at Harvard Medical School; Alain Rook, MD, Professor of Dermatology and Director of the Cutaneous Lymphoma Program at Penn Medicine; and Joel M. Gelfand, MD, MSCE, Associate Professor of Dermatology and Medical Director of the Clinical Studies Unit at Penn Medicine.
Visit the following websites to read more about the clinical trial:
Early Results Promising for Topical Gel Treatment for CTCL (Online First) from Oncology Times
Topical Gel Proves Safe, Effective Treatment for Patients with Skin T Cell Lymphoma from Cancer News Source
The 2015 summer issue of the Stanford Medicine Magazine featured an excellent article about cutaneous lymphoma, including explanations of the disease and highlighting total skin electron radiation and stem cell transplant treatments.
Click here to read the article republished with permission by Stanford Medicine Magazine.
This annual scientific meeting provides a forum for researchers, scientists and clinicians from around the world to come together to share updates and latest findings related to the biology of T-cell lymphoma as well as information about treatment options using existing therapies along with new therapies on the horizon.
Although the meeting covers all T-cell lymphomas, there were several presentations specific to cutaneous T-cell lymphoma and posters presented by experts in the field. Drs. Pierluigi Porcu, Youn Kim, Madeleine Duvic, Christiane Querfeld and Miles Prince were among the cutaneous lymphoma presenters.
The major take-away from this meeting was research to understand the molecular basis of T-cell lymphomas is ongoing and is essential to help ensure that new drugs and other therapies being developed specifically target the different types of T-cell lymphomas.
Susan Thornton, CLF's CEO, attended the Forum on behalf of the Foundation. Click here to read her highlights from the Forum.
Marianne Tawa, RN, NP, of the Center for Cutaneous Oncology at Dana Farber, has been recognized with a DAISY Award, a quarterly honor given to an extraordinary member of the nursing department. Tawa received the award during a surprise ceremony on Feb. 4. Marianne is the Vice President of the Cutaneous Lymphoma Foundation's Board of Directors.
Tawa's nomination for the award came from Betsy Doucette, whose husband, Paul, was treated for cutaneous T-cell lymphoma. In her nomination, Doucette highlighted Tawa's constant support throughout her husband's seven years of treatment.
"Marianne gave Paul such thorough, thoughtful, and compassionate care and friendship through the years, and she was the source of strength and encouragement he needed to fight his battles," Betsy says. "Paul's entire family and I are deeply grateful."
Dana-Farber is one of approximately 1,500 hospitals that participate in the DAISY Award program. The DAISY Foundation (Diseases Attacking the Immune System) established the award in memory of J. Patrick Barnes, whose parents created the foundation in Patrick's memory after experiencing firsthand the skills, care, and compassion of nurses.
(Article copied with permission from the Dana Farber's "Inside the Institute" newsletter.)
This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.